Antibodies against the following proteins were purchased from Cell Signaling Technology (USA):
phosphorylated (p‐) AMPKα (Thr172) (used in experiments at 1:1,000 dilution),
total AMPKα (at 1:1,000 dilution), p‐ACC (Ser79) (at 1:1,000 dilution), total ACC (at 1:1,000 dilution),
p‐ERK1/2 (Thr202/Tyr204) (at 1:2,000 dilution),
total ERK1/2 (at 1:2,000 dilution), p‐p38 (Thr180/Tyr182) (at 1:1,000 dilution), total p38 (at 1:1,000 dilution),
p‐JNK1/2 (Thr183/Tyr185) (at 1:1,000 dilution),
total JNK1/2(at 1:1,000 dilution),
p‐mTOR (Ser2448) (at 1:1,000 dilution), total mTOR (at 1:1,000 dilution),
p‐p70S6K (Thr389) (at 1:1,000 dilution),
total p70S6K (at 1:1,000 dilution) and HRP‐linked secondary antibody (at 1:3,000 dilution). The
antibody against GAPDH (at 1:3,000 dilution) was purchased from Abclonal. In addition, the following reagents were used:
thymoquinone (TQ; Sigma‐Aldrich),
phenylephrine (PE; Tokyo Chemical Industry) and compound C (CpC; Selleck).
Chen H., Zhuo C., Zu A., Yuan S., Zhang H., Zhao J, & Zheng L. (2021). Thymoquinone ameliorates pressure overload‐induced cardiac hypertrophy by activating the AMPK signalling pathway. Journal of Cellular and Molecular Medicine, 26(3), 855-867.